Merck KGaA Stock
€149.65
Your prediction
Merck KGaA Stock
Pros and Cons of Merck KGaA in the next few years
Pros
Cons
Performance of Merck KGaA vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Merck KGaA | -0.630% | -2.698% | -10.309% | -3.108% | 3.960% | -10.843% | 59.951% |
Bayer AG | -2.610% | -2.163% | 0.691% | -49.344% | -22.036% | -48.670% | -55.908% |
Elanco Animal Health Inc. | -0.490% | -7.742% | -30.809% | 7.930% | -13.624% | -61.357% | - |
Johnson & Johnson | -0.420% | 3.448% | 2.199% | -6.985% | 0.438% | -0.975% | 22.498% |
![Hi, I am the sharewise BeanCounterBot. I am digging through tons of financial data to give you a brief summary. I am not perfect but hopefully helpful](/assets/chat-9828e04e1fb016b9d37708c0616b4967f024986270e9f6aa795b8e10e9795a24.png)
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.It appears that Merck, operating under the US symbol MKGAF, showcases stable financial performance within the pharmaceuticals industry. The company has shown consistent growth in total assets and net income in recent years, and its overall financial position and liquidity seem to be in good shape.
In conclusion, Merck's financials reveal a generally positive situation for the company, with growth in total assets, net income, and operating cash flows. However, certain areas, such as increased long-term debt, negative net tangible assets, and changes in net working capital necessitate careful monitoring. As an analyst, monitoring Merck's financial performance and management strategies will be crucial to ensure sustained growth and stability in the coming years.
Comments
News
![2 Magnificent Stocks to Buy With $500: https://g.foolcdn.com/editorial/images/783078/doctor-with-patient-talking.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNnZZYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4f6f558904f0741b349a665276e83aa348896608/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/doctor-with-patient-talking.jpg?locale=us)
2 Magnificent Stocks to Buy With $500
Some might hesitate to invest in stocks during a bull run, like the one we are experiencing. They argue that equities are likely to be overvalued. However, it's possible to find reasonably valued
![This Recent FDA Approval Is Bad News for Pfizer: https://g.foolcdn.com/editorial/images/781336/a-frustrated-investor-reviewing-multiple-charts-and-reports.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0hGYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--7039de35359f40afa7561b5e48a8b3d0af28d582/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/a-frustrated-investor-reviewing-multiple-charts-and-reports.jpg?locale=us)
This Recent FDA Approval Is Bad News for Pfizer
It's no secret why Pfizer (NYSE: PFE) stock has been struggling this year. Investors are worried about how well the company will be able to do in light of waning demand for its COVID-19 vaccine and